country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P4676A

Copy Link Print Information

Lys-(Des-Arg9,Leu8)-Bradykinin TFA

Lys-(Des-Arg9,Leu8)-Bradykinin TFA is a selective bradykinin B1 receptor (BDKRB1) antagonist. Lys-(Des-Arg9,Leu8)-Bradykinin TFA inhibits local inflammatory edema. Lys-(Des-Arg9,Leu8)-Bradykinin TFA induces the production of systemic acute-phase proteins. Lys-(Des-Arg9,Leu8)-Bradykinin TFA is applicable to research related to peptidoglycan-polysaccharide-induced acute arthritis.

For research use only. We do not sell to patients.

Formula: C₄₉H₇₆F₃N₁₃O₁₃
Molecular Weight:1112.20

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Custom Peptide Synthesis

Lys-(Des-Arg9,Leu8)-Bradykinin TFA Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

Bradykinin B1 Receptor (B1R)

All Bradykinin Receptor Isoforms :

In Vivo

Lys-(Des-Arg9,Leu8)-Bradykinin (0.5-5 mg/kg per day; s.c.; continuous infusion; 6 days) TFA significantly reduces PG-APS-induced hindpaw edema at 72 hours and increases liver T-kininogen content by 45% at 24 hours in female Lewis rats with PG-APS-induced arthritis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Lewis rats (female, 150-170 gm, PG-APS-induced arthritis)^[1]
Dosage:

500 µg/kg per day; 5 mg/kg per day
Administration:

s.c.; continuous infusion; 6 days
Result:

Showed no significant effect on hindpaw edema or joint diameter at 24, 48, or 72 hours after PG-APS injection at 500 µg/kg per day.
Significantly reduced hindpaw volume at 72 hours after PG-APS injection at 5 mg/kg per day.
Increased liver T-kininogen content to 413 µg/gm of liver, a 45% increase compared to control, at 24 hours after PG-APS injection at 5 mg/kg per day.
Showed no significant effect on liver T-kininogen content at 72 hours after PG-APS injection at 5 mg/kg per day.

Chemical Information

Molecular Weight 1112.20
Formula C₄₉H₇₆F₃N₁₃O₁₃
Sequence

Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu
Sequence Shortening

KRPPGFSPL
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Blais C Jr, et al. Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat. Arthritis Rheum. 1997;40(7):1327-1333. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote